Research Reports
Emcure Pharmaceuticals Shares
Emcure Pharmaceuticals
DMAT
PUBLIC LIMITED
Price Chart
1W
1M
1Y
MAX
High
-
Low
-
Return
-
No data available
Buy Sell Emcure Pharmaceuticals
As of May 21, 2026, Emcure Pharmaceuticals Ltd, Listed Shares are trading at ₹1,631.00 per share.
ISIN
INE168P01015
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
10
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Shares
18,11,52,116
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Market Cap
29,545.91 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Profit After Tax
527.58 Cr
It is the final profit left over after subtracting all operating and non operating items from net revenue.
Total Revenue
6,671.57 Cr
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
P/E
56
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
P/B
10.24
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Pharmaceuticals
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Listed
Category is defined as a class or division of things regarded as having particular shared characteristics.
Cashflow - Operations
1,097.24 Cr
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
About Emcure Pharmaceuticals
Company Overview:
- Emcure was incorporated by Mr. Satish Mehta in 1981; the company commenced operations in 1983 in Pune, Maharashtra.
- Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
- The group has 13 manufacturing facilities across India and 5 R&D center's. The manufacturing facilities can manufacture pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs.
- Emcure is an R&D driven company and their core strength lies in their ability to research, develop and manufacture in house specialty pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry.
- Target market across 70 countries, with a strong presence in INDIA, Europe and Canada.
- Emcure Pharmaceuticals sales in India contributed 53.16% of their total revenue from operation and rest 46.84% outside of India in FY2023.
- As of September 30, 2023, Emcure had been granted 201 patents and had 33 pending patent applications in several countries, and had submitted 102 DMFs for APIs with the USFDA.
Want to See a Detailed Investment Analysis?
Explore in-depth financial analysis, performance metrics, and key disclosures.
Emcure Pharmaceuticals Media
News
Articles
Videos
Emcure Pharma inaugurates R&D centre in Ahmedabad
22 Jan 2025
• Express Pharma
Emcure Pharma Brings product range for menopause wellness
04 Sep 2024
• The Economic Times
Emcure Pharma Partners With Moms To Normalize Public Breastfeeding For World Breastfeeding Week
01 Aug 2024
• BW Healthcare
Frequently Asked Question (FAQs)
Where can I find the annual report of Emcure Pharmaceuticals Ltd Ltd?
The annual report of Emcure Pharmaceuticals Ltd Ltd is available in the annual report section.
How to buy Emcure Pharmaceuticals Ltd Listed Shares?
Please find below the procedure for buying Emcure Pharmaceuticals Ltd Listed Shares at Planify.
• 1. You confirm booking of Emcure Pharmaceuticals Ltd Listed Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling Emcure Pharmaceuticals Ltd Listed Shares is 6 months after listing. Hence you can’t sell Emcure Pharmaceuticals Ltd Listed Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.
What is the lock-in period of Emcure Pharmaceuticals Ltd Listed Shares?
Lock-in period of Emcure Pharmaceuticals Ltd Listed Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Emcure Pharmaceuticals Ltd Listed Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Emcure Pharmaceuticals Ltd Listed Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.
See More
Emcure Pharmaceuticals
₹ 1,631
